eFFECTOR Therapeutics, Inc.
EFTR
$0.0002
$0.000.00%
OTC PK
| 03/31/2024 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -12.64% | 13.43% | |||
| Gross Profit | 12.64% | -13.43% | |||
| SG&A Expenses | 22.42% | 0.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.35% | 9.46% | |||
| Operating Income | 2.35% | -9.46% | |||
| Income Before Tax | 3.24% | -9.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.24% | -9.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.24% | -9.96% | |||
| EBIT | 2.35% | -9.46% | |||
| EBITDA | 2.33% | -9.44% | |||
| EPS Basic | 36.70% | -1.75% | |||
| Normalized Basic EPS | 36.71% | -1.68% | |||
| EPS Diluted | 36.70% | -1.75% | |||
| Normalized Diluted EPS | 36.71% | -1.68% | |||
| Average Basic Shares Outstanding | 52.87% | 8.07% | |||
| Average Diluted Shares Outstanding | 52.87% | 8.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||